Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 9;6(1):1119-1126.
doi: 10.1177/26884844251387017. eCollection 2025.

Real-World Safety and Effectiveness of Ganirelix for Ovarian Stimulation in Chinese Women: A Multicenter, Prospective, Single-Arm, Observational Study

Jia Li  1 , Fei Gong  2 , Lihong Geng  3 , Xiaohong Wang  4 , Zhaolian Wei  5 , Jianqiao Liu  6 , Yong Zeng  7 , Jue Wang  8 , Keith Gordon  9 , Sisi Chen  8 , Rui Yang  1 , Rong Li  1
Affiliations

Real-World Safety and Effectiveness of Ganirelix for Ovarian Stimulation in Chinese Women: A Multicenter, Prospective, Single-Arm, Observational Study

Jia Li et al. Womens Health Rep (New Rochelle). .

Abstract

Background: This study aimed to evaluate the safety and effectiveness of ganirelix acetate for Chinese women undergoing ovarian stimulation (OS) in real-world clinical practice.

Methods: This multicenter (16), prospective, single-arm, observational, post-authorization safety study included 1025 Chinese women receiving at least one dose of ganirelix during OS. Safety endpoints were collected until 5 weeks after embryo transfer. The investigator assessed the causality and seriousness of an adverse event (AE). Effectiveness and neonatal outcomes were collected from medical records and phone call follow-ups. The study had a probability of >95% to observe an AE occurring at 0.3% with a sample size of 1000.

Results: The occurrence of overall AEs, drug-related AEs, and serious AEs (SAEs) was 12.1% (124/1025), 1.3% (13/1025), and 2.4% (25/1025), respectively. None of the SAEs were drug related, according to the investigator. Two (0.2%) patients discontinued treatment due to an AE. The most reported AE was ovarian hyperstimulation syndrome (4.8%, 49/1025), among which 21 cases were reported as SAE. The proportion of patients with a premature luteinizing hormone (LH) rise >10 IU/L) was 2.5% (26/1025), and one patient had a premature ovulation. The live birth rate was 34.9% (358/1025) per start cycle with a cumulative live birth rate of 42.1% (432/1025). Neonatal malformations occurred in 1.3% (7/523) of the neonates.

Conclusions: This study indicates that the safety profile and effectiveness of ganirelix were clinically acceptable, and no new safety signals emerged in real-world clinical practice for Chinese women with OS. The study was registered on Chinadrugtrial.org (identifier: CTR20150284) (http://www.chinadrugtrials.org.cn) and ENCePP.eu (identifier: EUPAS8737) (https://catalogues.ema.europa.eu).

Keywords: ganirelix; gonadotropin-releasing hormone antagonist; ovarian stimulation; safety.

PubMed Disclaimer

References

    1. World Health Organization. Infertility prevalence estimates, 1990-2021. 2023. Available from: https://www.who.int/publications/i/item/978920068315
    1. Out HJ, Mannaerts BM. The gonadotrophin-releasing hormone antagonist ganirelix—History and introductory data. Hum Fertil (Camb) 2002;5(1):G5–G10; discussion G10-12, G41-18; doi: 10.1080/1464727992000199771 - DOI - PubMed
    1. Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15(7):1490–1498; doi: 10.1093/humrep/15.7.1490 - DOI - PubMed
    1. Qiao J, Lu G, Zhang HW, et al. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: High efficacy and pregnancy rates. Gynecol Endocrinol 2012;28(10):800–804; doi: 10.3109/09513590.2012.665103 - DOI - PubMed
    1. Al-Inany HG, Abou-Setta AM, Mansour RT, et al. Efficacy and safety of highly purified HMG vs. recombinant follicle stimulating hormone: A meta-analysis. Fertil Steril 2007;88:S35–S36; doi: 10.1016/j.fertnstert.2007.07.128 - DOI

LinkOut - more resources